Mitochondrial DNA (mtDNA) has increased susceptibility to damage due to its close proximity to the site of reactive oxygen species production, lack of introns and protective histones, and less efficient DNA repair mechanisms than nuclear DNA. The relationship between mtDNA copy number in peripheral blood leukocytes (PBLs) and the risk of soft tissue sarcoma (STS) has not been investigated. In this study, we determined the relative mtDNA copy number in PBLs of 325 patients (cases) with histologically confirmed STS and 330 healthy controls that were frequency matched to cases according to age, sex and ethnicity. Cases had a significantly lower mtDNA copy number than controls (0.93 ± 0.49 for cases versus 1.23 ± 0.59 for controls; P < 0.001). In analyses stratified by sex, ethnicity and smoking status, mtDNA copy number was lower in the cases than in controls in any stratum. Using the median mtDNA copy number in controls as a cutoff, individuals with lower mtDNA copy number were associated with a significantly increased risk of STS compared with those with higher mtDNA copy number (adjusted odds ratio, 2.71; 95% confidence interval, 1.94-3.82). There was a significant dose-response relationship between reduced mtDNA copy number and increased risk of STS in tertile and quartile analyses. The present study provides the first epidemiologic evidence that reduced mtDNA copy number in PBLs is significantly associated with an increased risk of STS, thereby suggesting an important role of mtDNA in STS development.
Introduction
Soft tissue sarcomas (STSs) consist of a heterogeneous group of rare malignant tumors of the connective tissue, including muscle, fat and fibrous structures that are derived mainly from embryonic mesoderm (1) . Approximately 11 000 new STS cases are diagnosed annually in the USA, accounting for 0.6% of all adult malignancies (2) . Approximately 50% of STS patients are diagnosed with advanced diseases (defined as regional or metastatic), who have median progression-free interval of 4-6 months and only a few could survive long term (3) (4) (5) . This fact emphasizes the need to develop biomarkers to help identify the populations at highest risk of developing STS for targeted prevention and early diagnosis of this malignant disease.
Mitochondria are the essential eukaryotic organelles that play a wide variety of roles in fundamental cellular processes such as energy metabolism, proliferation, immune response, apoptosis and oxidative phosphorylation. Mitochondria are the primary target of reactive oxygen species (6) (7) (8) (9) . Human mitochondrial DNA (mtDNA) is a maternally inherited genome consisting of 16 569 bp of circular double-stranded DNA molecule. The mtDNA contains only 37 genes: 13 for essential components of the electron transport chain, 22 for mitochondrial transfer RNAs and 2 for ribosomal RNAs (10) . Each mitochondrion contains 2-10 mtDNA molecules (11) . Compared with nuclear DNA, mtDNA lacks introns and protective histones, has diminished DNA repair capacity and is therefore particularly susceptible to reactive oxygen species and other types of damage (12) . As a consequence, the mutation rate for mtDNA is substantially greater than that of nuclear DNA (13) . In humans, the number of mtDNA copies per cell varies significantly, depending on cell type or tissue origin-from several hundred to more than 10 000 copies per cell (14) . The copy number of mtDNA in the cell is related to the energy demands that sustain normal functions (15) . There have been reports that mtDNA copy number is affected by both endogenous and exogenous factors, such as age, hormones, dietary factors, stress, environmental oxidants/antioxidants and reaction to oxidative damage (16, 17) . Numerous studies have reported somatic alterations of mtDNA copy number in human malignancies in a cancer type-specific manner, including increased copy numbers in acute lymphoblastic leukemia (18) , non-Hodgkin lymphoma (19) , and cancers in colon, rectum, esophagus, head and neck, oarium, endometrium, thyroid and prostate gland (20) (21) (22) (23) (24) (25) (26) , and decreased copy numbers in gastric, liver, breast, lung and renal cancers (25, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . In accordance with these studies, several recent studies have found significant association between mtDNA copy number in peripheral blood leukocytes (PBLs) (as a surrogate of constitutive genetic background) and the risk of several malignancies, including liver, breast, lung, colorectal, renal cancers (16, (38) (39) (40) (41) and non-Hodgkin lymphoma (42) . However, whether mtDNA copy number in PBLs is associated with the risk of STS remains to be determined.
In this study, we measured mtDNA copy number using real-time quantitative polymerase chain reaction (qPCR) in a case-control study of STS and evaluated the association between mtDNA copy number and the risk of developing STS. To our knowledge, this is the first epidemiologic study to investigate the association of mtDNA copy number with STS susceptibility.
Materials and methods

Study population and epidemiologic data
A total of 325 patients with STS (cases) and 330 healthy controls were consecutively recruited from 1 November 2010 to 31 January 2012. Cases were from the University of Texas MD Anderson Cancer Center through a daily review of computerized appointment schedules. No restriction on age, sex, ethnicity or disease stage was used for case recruitment. Control subjects without a previous history of cancer were identified from the rosters of Kelsey Seybold Clinic, the largest multispecialty physician group in the Houston metropolitan area. Control subjects were matched to cases by age (±1 year), sex, ethnicity and residential region and were recruited during the same time period as the cases. All participants were interviewed so that information could be collected on demographics, smoking history, alcohol consumption, family history of cancer and medical history. Baseline blood samples were collected after the interview. This study was approved by institutional review boards at MD Anderson and Kelsey Seybold. Informed consent was obtained from all participants. The response rates for cases and controls were 92 and 77%, respectively. mtDNA copy number assessment by qPCR High-quality genomic DNA was extracted from participants' peripheral blood using the QIAamp Maxi DNA kit (Qiagen, Valencia, CA) according to the Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; HGB, human globulin; mtDNA, mitochondrial DNA; PBLs, peripheral blood leukocytes; qPCR, quantitative polymerase chain reaction; SD, standard deviation.
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manufacturer's protocol. The relative mtDNA copy number was measured by qPCR-based method as described previously (43, 44) with some modifications (39) . Two pairs of primers were designed and used for the relative quantification of mtDNA copy number. One primer pair was used for the amplification of the MT-ND1 gene in mtDNA. The primer sequences were as follows: forward primer (ND1-F), 5′-CCTAAAACCCGCCACATCT-3′; reverse primer (ND1-R), 5′-GAGCGATGGTGAGAGCTAAGGT-3′. Another primer pair was used for the amplification of the nuclear gene human globulin (HGB). The primer sequences were as follows: forward primer (HGB-1), 5′-GTGCACCTGACTCCTGAGGAGA-3′; reverse primer (HGB-2), 5′-CCTTGATACCAACCTGCCCAG-3′.
The PCR reaction mixture (14 μl) for the mtDNA amplification consisted of 1× SYBR Green Mastermix (Applied Biosystems, Foster City, CA), 200 nmol/l ND1-F primer, 200 nmol/l ND1-R primer and 5 ng of genomic DNA. The PCR reaction mixture (14 μl) for HGB gene amplification consisted of 1× SYBR Green Mastermix, 200 nmol/l HGB-1 primer, 200 nmol/l HGB-2 primer and 5 ng of genomic DNA. The thermal cycling conditions were 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C (for MT-ND1 gene amplification) or 56°C (for HGB amplification) for 1 min. Each sample was run in duplicate in a 384-well plate. Real-time PCR was performed in the 7900HT Sequence Detection System (Applied Biosystems). The qPCR procedures for mtDNA and HGB were always performed on separate 384-well plates with the same samples in the same well positions to avoid possible position effect. During each run, negative controls (water), a calibrator DNA and a standard curve were included. Each plate contained randomly selected samples to have equal representation of cases and controls. The lab personnel were blinded to case-control status. For the standard curve, a reference DNA sample was serially diluted by using a 2-fold increment dilution to generate a six-point standard curve between 20 and 0.625 ng of DNA in each reaction. The R 2 correlation for each standard curve was ≥0.98, with acceptable standard deviation (SD) set at 0.3 for the Ct values. If the result was found to be out of the acceptable range, the same sample was repeated. The ratio of the mtDNA copy number to the single gene (HGB) copy number was determined for each sample using standard curves. This ratio was proportional to the mtDNA copy number in each sample. The ratio for each sample was then normalized to a calibrator DNA sample to standardize between different runs. For testing the interassay variation, two samples with relatively low and high mtDNA copy number were tested using three different runs.
Statistical analysis
All statistical analyses were done with the Stata 10.1 statistical software package (StataCorp, College Station, TX). The difference in the distribution of host characteristics between the cases and the controls was evaluated by Pearson χ 2 test for categorical variables (sex and ethnicity) and Student's t-test for continuous variables (age and mtDNA copy number). The correlation between age and mtDNA copy number was determined using Spearman correlation analysis. The mtDNA copy number was also analyzed as categorical variables based on a cutoff point at the median, tertile or quartile values in the controls. The association between STS risk and mtDNA copy number was estimated by an unconditional multivariate logistic regression to determine the adjusted odds ratio (aOR) along with corresponding 95% confidence interval (95% CI), adjusting for age, sex, ethnicity and smoking status. All statistical tests were two sided, and the level of statistical significance was set at P < 0.05.
Results
A total of 325 patients with STS and 330 healthy controls were included in this study. The mean age (±SDs) of STS cases and controls We measured mtDNA copy number using real-time qPCR in all samples from the case and control groups. The normalized mtDNA copy number was 0.93 ± 0.49 for cases and 1.23 ± 0.59 for controls (P < 0.001). In stratified analyses by sex, ethnicity (white and others) and smoking status (ever and never), lower mtDNA copy number was found in PBLs of STS cases than in those of controls in all strata (Table II) . In the case group, increasing age was significantly associated with lower levels of mtDNA. On the contrary, in the control group, increasing age was significantly associated with higher levels of mtDNA (Table III) . There was no significant correlation between mtDNA copy number and tumor size (greatest dimension in centimeters) at diagnosis, stage, grade, metastasis or smoking status (data not shown).
We next performed a multivariate unconditional logistic regression analysis adjusting for age, sex, ethnicity and smoking status to assess the association between mtDNA copy number and the risk of STS (Table IV) . When individuals were dichotomized into high and low groups based on the median mtDNA copy number value in healthy controls, we observed that lower mtDNA copy number (<1.12) in PBLs was associated with a 2.72-fold increased risk of STS (aOR, 2.72; 95% CI, 1.94-3.82). When participants were categorized further into three groups according to the tertile values of mtDNA copy number in healthy controls, we observed a significant dose-response relationship between increased risk of STS and lower mtDNA copy number. That is, when the first (≥1.40) tertile was used as the reference group, the aORs for the second (0.95-1.39) and third (<0.95) tertiles were 2.40 (95% CI, 1.47-3.91) and 5.67 (95% CI, 3.85-8.98), respectively (P trend < 0.001). Similarly, when participants were categorized further into four groups according to the quartile values of mtDNA copy number in healthy controls, we also observed a significant dose-response relationship between increased risk of STS and lower mtDNA copy number. When the first (≥1.51) quartile was used as the reference group, the aORs for the second (1.12-1.50), third (0.85-1.11) and fourth (<0.85) quartiles were 3.24 (95% CI, 1.77-5.96), 3.55 (95% CI, 1.95-6.47) and 8.01 (95% CI, 4.51-14.20), respectively (P trend < 0.001). These observations were similar when patients were stratified by sex, age or among whites only (Table V) .
Discussion
In this study, we found that STS cases had a significantly lower mtDNA copy number than controls in any stratum. We further assessed the association between mtDNA copy number and STS risk and found that individuals with lower mtDNA copy number exhibited a nearly 3-fold increased risk of STS compared with those with higher mtDNA copy number when using the median mtDNA copy number in controls as a cutoff. When participants were categorized further into three or four groups according to tertile or quartile mtDNA copy number values in controls, we observed a significant dose-response relationship between reduced mtDNA copy number and increased risk of STS.
The increased STS risk in individuals with lower mtDNA copy number may be attributed to the alteration of mitochondrial respiratory function. Normal cells derive their energy mainly from aerobic respiration, whereas cancer cells derive mainly from fermentation due to the poor-oxygen tumor microenvironment (45) . Injury to the respiratory machinery is a critical event in carcinogenesis. Cancer cells exhibit enhanced generation of adenosine triphosphate by glycolysis and decreased oxidative phosphorylation (Warburg effect) (46) . mtDNA depletion promotes cancer cells to become resistant to apoptosis (47) . mtDNA depletion in cancer cells leads to epithelial-mesenchymal transition (48) , which plays an important role in tumor formation and progression to metastatic carcinomas (49) . On the other hand, depletion of mtDNA was reported to activate nuclear factor-kappa B/Rel factors through inactivation of nuclear factorkappa B inhibitor; dysregulation of nuclear factor-kappa B signaling plays a critical role in inflammation, apoptosis and cell development and is clearly linked to various cancer malignant transformation (50) . All these basic research data provide biological plausibility to explain that lower mtDNA copy number is associated with malignant disease development. Several previous studies reported that low mtDNA content in PBLs was significantly associated with an increased risk of cancer. In a classic twin study, Xing et al. (39) designed that low mtDNA copy number in PBLs is associated with increased risk of renal cell carcinoma and mtDNA content appears to have high heritability. Zhao et al. (38) found that compared with healthy controls, individuals with low mtDNA content in PBLs had a significantly increased risk of hepatocellular carcinoma. Recently, Yu et al. (51, 52) found that levels of circulating cell-free mtDNA in serum and tumor tissues of Ewing's sarcoma patients were significantly lower than in healthy controls and associated with the status of tumor metastasis. These results are consistent with our present finding that lower mtDNA copy number in PBLs increased STS risk. However, further studies are needed to elucidate the molecular mechanisms underlying this association.
Our results also showed that in the control group, increasing age was significantly associated with a higher level of mtDNA. It is possible that the mtDNA copy increase may be a compensatory response to the decrease of mitochondrial respiratory function (53) . In the case group, increasing age was significantly associated with lower level of mtDNA copy number. This observation is in line with a previous study (30) and maybe due to the cancer-related, reactive oxygen species-accelerated accumulation of mtDNA damage seen with increasing age.
As with any retrospective case-control study of intermediate biomarkers, the main limitation of this study is the possibility of 'reverse causation', i.e. the lower mtDNA copy number in STS cases may be the result rather than the cause of the disease. We only included newly diagnosed STS cases and collected blood samples before treatment, which should reduce the impact of disease status and treatment on mtDNA copy number. We did not observe significant relationship between any clinical variables (tumor size, stage, grade and metastasis) and mtDNA copy number, arguing against the effect of disease status on mtDNA copy number. The sample size of this study is sufficient for a single marker study, although it is still relatively small due to the rarity of STS. Large studies, particularly in the prospective setting, are needed to confirm our findings.
In summary, our study provides an epidemiologic evidence for the association of mtDNA copy number in PBLs with the risk of STS. We showed a significant association between low mtDNA copy number in PBLs and increased risk of STS with a clear dose-response effect. Increasing age was significantly associated with lower level of mtDNA in STS patients. To the best of our knowledge, this is the first epidemiological study to evaluate the relationship between mtDNA copy number in PBLs and the risk of STS. Further efforts are needed to explore the biological role of mtDNA copy number alteration in the development of STS and its clinical significance in STS diagnosis and treatment.
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